Evidence map›Paper›PMID 39131669›Full record

ArticleGastro hep advances2022

Circulating IgG4

Rachele Ciccocioppo, Giulia De Marchi, Valeria Zuliani, Annalisa Adamo, Antonio Amodio, Pietro Campagnola, Enrico Maria Gabrieletto, Nicolò de Pretis, Stefano Ugel, Pietro Delfino and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rachele CiccocioppoGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Giulia De MarchiGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Valeria ZulianiGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Annalisa AdamoHematology Unit, Department of Medicine, University of Verona, Verona, Italy.
Antonio AmodioGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Pietro CampagnolaGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Enrico Maria GabrielettoGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Nicolò de PretisGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Stefano UgelImmunology Unit, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Pietro DelfinoPathology Unit, Department of Diagnostics and Public Health, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.
Mauro KramperaHematology Unit, Department of Medicine, University of Verona, Verona, Italy.
Luca FrulloniGastroenterology Unit - Pancreas Institute, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Type 1 autoimmune pancreatitis (AIP) is an IgG4-related disease whose diagnosis is challenging. The aim of this study was to investigate the diagnostic value of circulating total and IgG4 Methods: Patients with type 1 AIP (n = 19) were prospectively enrolled in a tertiary center together with patients suffering from type 2 or not otherwise specified (NOS) AIP (n = 10), pancreatic adenocarcinoma (n = 17), chronic pancreatitis (n = 20), and intraductal papillary mucinous neoplasia or chronic asymptomatic pancreatic hyperenzymemia (n = 21) as control groups. Flow cytometry was used to measure the total plasmablast and IgG4 Results: Total plasmablast quantification was capable of discriminating type 1 AIP from all the other pancreatic disorders with a sensitivity of 47% and a specificity of 81%, according to a cutoff of 4500 cells/mL (AUC = 0.738), whereas IgG4 Conclusion: IgG4

Indexed as

Autoimmune PancreatitisBiomarkerDiagnosisPlasmablasts

Identifiers

PMID39131669
PMCPMC11307817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.